A Study to Assess the Safety, Tolerability, and Immunogenicity of 2 Antigen Doses of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process Administered to Healthy Infants at 2, 4, and 6 Months of Age.
Phase of Trial: Phase III
Latest Information Update: 26 May 2017
At a glance
- Drugs Hepatitis B vaccine recombinant (Primary)
- Indications Hepatitis B
- Focus Pharmacodynamics
- Sponsors Merck & Co
- 05 May 2011 Results published in the Pediatric Infectious Disease Journal.
- 29 Oct 2009 Results were presented at IDSA 2009.
- 12 May 2009 Actual number of patients (1718) added as reported by ClinicalTrials.gov
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History